Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

IF 2.9 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Saade Abdalkareem Jasim , Irina M. Farber , Sara Abdalrazzaq M. Noraldeen , Pooja Bansal , Hashem O. Alsaab , Bekhzod Abdullaev , Adnan Taan Alkhafaji , Ahmed Hussien Alawadi , Hamza Fadhel Hamzah , Bahira Abdulrazzaq Mohammed
{"title":"Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment","authors":"Saade Abdalkareem Jasim ,&nbsp;Irina M. Farber ,&nbsp;Sara Abdalrazzaq M. Noraldeen ,&nbsp;Pooja Bansal ,&nbsp;Hashem O. Alsaab ,&nbsp;Bekhzod Abdullaev ,&nbsp;Adnan Taan Alkhafaji ,&nbsp;Ahmed Hussien Alawadi ,&nbsp;Hamza Fadhel Hamzah ,&nbsp;Bahira Abdulrazzaq Mohammed","doi":"10.1016/j.mvr.2024.104691","DOIUrl":null,"url":null,"abstract":"<div><p>Neoadjuvant targeting of tumor angiogenesis has been developed and approved for the treatment of malignant tumors. However, vascular disruption leads to tumor hypoxia, which exacerbates the treatment process and causes drug resistance. In addition, successful delivery of therapeutic agents and efficacy of radiotherapy require normal vascular networks and sufficient oxygen, which complete tumor vasculopathy hinders their efficacy. In view of this controversy, an optimal dose of FDA-approved anti-angiogenic agents and combination with other therapies, such as immunotherapy and the use of nanocarrier-mediated targeted therapy, could improve therapeutic regimens, reduce the need for administration of high doses of chemotherapeutic agents and subsequently reduce side effects. Here, we review the mechanism of anti-angiogenic agents, highlight the challenges of existing therapies, and present how the combination of immunotherapies and nanomedicine could improve angiogenesis-based tumor treatment.</p></div>","PeriodicalId":18534,"journal":{"name":"Microvascular research","volume":"154 ","pages":"Article 104691"},"PeriodicalIF":2.9000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microvascular research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0026286224000402","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Neoadjuvant targeting of tumor angiogenesis has been developed and approved for the treatment of malignant tumors. However, vascular disruption leads to tumor hypoxia, which exacerbates the treatment process and causes drug resistance. In addition, successful delivery of therapeutic agents and efficacy of radiotherapy require normal vascular networks and sufficient oxygen, which complete tumor vasculopathy hinders their efficacy. In view of this controversy, an optimal dose of FDA-approved anti-angiogenic agents and combination with other therapies, such as immunotherapy and the use of nanocarrier-mediated targeted therapy, could improve therapeutic regimens, reduce the need for administration of high doses of chemotherapeutic agents and subsequently reduce side effects. Here, we review the mechanism of anti-angiogenic agents, highlight the challenges of existing therapies, and present how the combination of immunotherapies and nanomedicine could improve angiogenesis-based tumor treatment.

结合免疫疗法和纳米药物,更好地规范基于血管生成的癌症治疗
针对肿瘤血管生成的新辅助疗法已被开发并批准用于治疗恶性肿瘤。然而,血管破坏会导致肿瘤缺氧,从而加剧治疗过程并引起耐药性。此外,治疗药物的成功输送和放射治疗的疗效需要正常的血管网络和充足的氧气,而完全的肿瘤血管病变会阻碍其疗效。鉴于上述争议,FDA 批准的抗血管生成药物的最佳剂量以及与其他疗法(如免疫疗法和使用纳米载体介导的靶向疗法)的结合,可以改善治疗方案,减少对大剂量化疗药物的需求,从而减少副作用。在此,我们回顾了抗血管生成药物的机制,强调了现有疗法面临的挑战,并介绍了免疫疗法和纳米药物的结合如何改善基于血管生成的肿瘤治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Microvascular research
Microvascular research 医学-外周血管病
CiteScore
6.00
自引率
3.20%
发文量
158
审稿时长
43 days
期刊介绍: Microvascular Research is dedicated to the dissemination of fundamental information related to the microvascular field. Full-length articles presenting the results of original research and brief communications are featured. Research Areas include: • Angiogenesis • Biochemistry • Bioengineering • Biomathematics • Biophysics • Cancer • Circulatory homeostasis • Comparative physiology • Drug delivery • Neuropharmacology • Microvascular pathology • Rheology • Tissue Engineering.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信